Protagonist Therapeutics, Inc

PTGX

Protagonist Therapeutics, Inc

PTGX

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-23Shares Purchased (TTM):0Shares Sold (TTM):395,809

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:69,298,844Shares Outstanding:65,087,847Institutional Ownership Pct.:106.47%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	420	194	128	114	169	140	97	131	356	173	187	231
Marketable Securities Current	362	354	439	462	402	435	322	338	208	150	155	90
Contract With Customer Asset Gross Current	-	-	-	-	-	-	165	-	0	300	10	-
Contract With Customer Asset Net Current	-	-	-	-	23	23	-	-	-	-	-	-
Receivables Long Term Contracts Or Programs	13	54	0	1	-	-	165	-	-	-	-	-
Prepaid Expense And Other Assets Current	8	12	10	10	9	9	8	8	7	5	4	4
Assets Current	807	613	578	586	603	606	592	477	571	628	356	325
Marketable Securities Noncurrent	67	73	79	103	102	124	140	115	31	-	-	2
Property Plant And Equipment Net	3	4	4	4	4	4	3	2	2	1	1	1
Restricted Cash Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	7	7	8	8	9	9	9	10	10	0	1	2
Assets	886	697	668	702	718	742	745	604	615	629	358	330
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	8	5	6	3	3	2	3	4	4	1	1
Contract With Customer Liability Current	-	-	-	-	-	-	-	-	-	0	0	0
Other Accounts Payable And Accrued Liabilities	22	17	28	23	15	12	24	21	15	16	19	25
Deferred Income Current	10	6	10	14	15	17	19	20	20	16	-	-
Accrued Income Taxes Current	-	-	-	-	-	2	3	1	3	3	-	-
Operating Lease Liability Current	2	2	2	2	2	2	1	0	-	0	1	2
Liabilities Current	37	35	45	45	36	35	47	45	42	40	21	28
Deferred Revenue Noncurrent	-	-	-	3	5	8	12	17	21	29	-	-
Operating Lease Liability Noncurrent	7	7	8	9	9	10	10	11	11	-	-	-
Liabilities	44	42	53	56	50	53	69	72	73	69	21	28
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,146	1,123	1,085	1,071	1,055	1,041	1,016	1,003	981	969	952	945
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	1	1	-0	0	-0	1	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-304	-467	-471	-426	-387	-352	-341	-472	-439	-408	-616	-643
Stockholders Equity	842	655	615	645	668	689	675	532	541	560	337	302
Liabilities And Stockholders Equity	886	697	668	702	718	742	745	604	615	629	358	330
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	180	180	180	180	180	180	180	180	180	90	90	90
Common Stock Shares Issued	65	64	63	62	62	62	61	60	59	59	58	58
Shares Outstanding	65	64	63	62	62	62	61	60	59	59	58	58

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	0.35%	22.85%	37.19%	-	-	-	-	-	-	-	-	-
2025	13.00%	32.56%	31.28%	9.63%	25.16%	38.98%	12.81%	11.28%	4.16%	13.51%	21.68%	17.31%
2024	9.15%	34.35%	56.18%	18.45%	23.06%	30.52%	-8.00%	-18.17%	-20.84%	41.37%	9.99%	10.89%
2023	-	-	-	-	-	-	11.81%	44.32%	60.74%	-5.27%	-13.45%	3.89%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	21.71	17.76	12.71	13.05	16.97	17.26	12.48	10.70	13.73	15.72	16.71	11.66
Quick Ratio	21.50	17.41	12.49	12.83	16.72	17.01	12.32	10.51	13.57	15.60	16.53	11.51
Working Capital	769.97M	578.91M	532.13M	541.48M	567.02M	570.75M	544.24M	432.19M	529.35M	587.64M	334.30M	297.01M
Leverage & Debt
Debt to Equity	0.05	0.06	0.09	0.09	0.07	0.08	0.10	0.14	0.14	0.12	0.06	0.09
Debt Ratio	0.05	0.06	0.08	0.08	0.07	0.07	0.09	0.12	0.12	0.11	0.06	0.08
Efficiency & Turnover
Asset Turnover TTM	0.09	0.10	0.07	0.32	0.31	0.30	0.79	0.69	0.68	0.72	0.20	0.00
Per Share Metrics
Diluted EPS TTM	1.17	-1.63	-2.05	0.72	0.82	0.89	4.23	2.77	2.77	2.55	-1.39	-2.37
Free Cash Flow Per Share TTM	1.98	-1.81	0.88	1.00	0.58	5.33	2.97	3.71	3.77	-1.05	-1.25	-2.02
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	85.15%	-192.36%	-343.63%	9.09%	11.46%	13.10%	58.20%	46.05%	47.71%	47.21%	-156.09%	-
Net Profit Margin TTM	121.01%	-154.88%	-282.83%	21.94%	24.88%	27.04%	63.34%	52.76%	53.26%	51.47%	-131.59%	-
Growth Metrics
Net Revenue Growth (1Y)	-67.24%	-64.36%	-89.41%	-35.39%	-34.45%	-34.02%	624.06%	-	-	36,565.08%	125.73%	-100.00%
Net Income Growth (1Y)	59.32%	-304.14%	-147.29%	-73.13%	-69.38%	-65.34%	-448.54%	-221.61%	-223.50%	-215.64%	-38.02%	7.98%
EPS Growth (1Y)	53.46%	-297.48%	-145.80%	-73.97%	-70.44%	-66.50%	-421.35%	-216.52%	-214.38%	-196.10%	-46.45%	-10.41%
Valuation Metrics
P/E TTM	97.49	-59.80	-42.66	92.28	67.46	54.19	8.64	16.27	12.50	10.86	-16.49	-7.03
P/B TTM	9.60	10.47	9.03	6.56	5.25	4.42	3.52	5.23	3.92	3.14	3.87	3.27
P/S TTM	117.96	92.63	120.66	20.25	16.78	14.65	5.47	8.58	6.66	5.59	21.69	-
Market Cap	8.08B	6.86B	5.55B	4.24B	3.51B	3.04B	2.38B	2.78B	2.12B	1.76B	1.30B	987.17M
Enterprise Value	7.66B	6.67B	5.42B	4.12B	3.34B	2.91B	2.28B	2.65B	1.77B	1.59B	1.11B	756.42M
Calculated Values
Free Cash Flow TTM	130.58M	-117.90M	56.08M	63.71M	37.10M	335.29M	182.80M	229.23M	230.85M	-64.16M	-70.85M	-119.49M
Net Debt	-420.37M	-194.00M	-128.68M	-114.00M	-168.83M	-139.88M	-97.47M	-131.35M	-355.87M	-172.79M	-186.95M	-230.75M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-23Sale

Owner: Waddill, William D.

Title: -

Shares: 9,000

Price/Share: $117.94

Value: $1,061,460.00

Shares Owned: 7,825

Relationship: Director

Ownership: Direct

2026-06-10Sale

Owner: Waddill, William D.

Title: -

Shares: 9,000

Price/Share: $107.68

Value: $969,120.00

Shares Owned: 7,825

Relationship: Director

Ownership: Direct

2026-05-29Sale

Owner: Waddill, William D.

Title: -

Shares: 9,000

Price/Share: $99.64

Value: $896,760.00

Shares Owned: 7,825

Relationship: Director

Ownership: Direct

2026-05-12Sale

Owner: Patel, Dinesh V Ph D

Title: President and CEO

Shares: 75,000

Price/Share: $100.12

Value: $7,509,000.00

Shares Owned: 523,478

Relationship: Director,Officer

Ownership: Direct

2026-05-08Sale

Owner: Giraudo, Bryan

Title: -

Shares: 5,130

Price/Share: $100.00

Value: $513,000.00

Shares Owned: 12,695

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-23	Waddill, William D.	Director	-	Direct	Sale	9,000	117.94	$1,061,460.00	7,825	4
2026-06-10	Waddill, William D.	Director	-	Direct	Sale	9,000	107.68	$969,120.00	7,825	4
2026-05-29	Waddill, William D.	Director	-	Direct	Sale	9,000	99.64	$896,760.00	7,825	4
2026-05-12	Patel, Dinesh V Ph D	Director,Officer	President and CEO	Direct	Sale	75,000	100.12	$7,509,000.00	523,478	4/A
2026-05-08	Giraudo, Bryan	Director	-	Direct	Sale	5,130	100.00	$513,000.00	12,695	4
2026-04-20	Ali, Asif	Officer	Chief Financial Officer	Direct	Sale	1,750	105.47	$184,572.50	59,003	4
2026-03-26	Molina, Arturo Md	Officer	Chief Medical Officer	Direct	Sale	15,000	104.79	$1,571,850.00	84,115	4
2026-03-26	Selick, Harold E	Director	-	Direct	Sale	24,000	105.00	$2,520,000.00	60,845	4
2026-03-26	Ali, Asif	Officer	Chief Financial Officer	Direct	Sale	24,765	104.24	$2,581,503.60	60,753	4
2026-03-25	Patel, Dinesh V Ph D	Director,Officer	President and CEO	Direct	Sale	54,641	101.00	$5,518,741.00	524,938	4
2026-02-17	Williams, Lewis T	Director	-	Direct	Sale	18,000	82.42	$1,483,560.00	7,825	4
2026-02-06	Waddill, William D.	Director	-	Direct	Sale	20,000	83.68	$1,673,600.00	7,825	4
2026-01-27	Ali, Asif	Officer	Chief Financial Officer	Direct	Sale	46,203	83.14	$3,841,317.42	60,320	4
2026-01-27	Molina, Arturo Md	Officer	Chief Medical Officer	Direct	Sale	5,000	82.00	$410,000.00	84,115	4
2026-01-27	Patel, Dinesh V Ph D	Director,Officer	President and CEO	Direct	Sale	4,068	83.19	$338,416.92	574,505	4
2026-01-20	Ali, Asif	Officer	Chief Financial Officer	Direct	Sale	8,588	82.48	$708,338.24	78,077	4
2026-01-20	Patel, Dinesh V Ph D	Director,Officer	President and CEO	Direct	Sale	34,438	82.48	$2,840,446.24	580,505	4
2026-01-20	Molina, Arturo Md	Officer	Chief Medical Officer	Direct	Sale	9,514	82.48	$784,714.72	97,266	4
2025-11-17	Molina, Arturo Md	Officer	Chief Medical Officer	Direct	Sale	2,712	84.77	$229,896.24	81,180	4
2025-10-10	Waddill, William D.	Director	-	Direct	Sale	12,000	78.53	$942,360.00	5,130	4
2025-09-22	Waddill, William D.	Director	-	Direct	Sale	4,000	64.25	$257,000.00	5,130	4
2025-08-27	Waddill, William D.	Director	-	Direct	Sale	4,000	59.25	$237,000.00	9,130	4
2025-07-25	Patel, Dinesh V Ph D	Director,Officer	President and CEO	Direct	Sale	10,415	54.78	$570,533.70	520,603	4
2025-07-23	Patel, Dinesh V Ph D	Director,Officer	President and CEO	Direct	Sale	17,520	54.79	$959,920.80	531,018	4
2025-06-10	Molina, Arturo Md	Officer	Chief Medical Officer	Direct	Sale	10,000	57.03	$570,300.00	83,892	4
2025-04-22	Ali, Asif	Officer	Chief Financial Officer	Direct	Sale	1,756	46.00	$80,776.00	61,065	4
2025-03-17	Waddill, William D.	Director	-	Direct	Sale	4,000	54.25	$217,000.00	13,130	4
2025-03-13	Molina, Arturo Md	Officer	Chief Medical Officer	Direct	Sale	30,514	55.74	$1,700,850.36	83,892	4
2025-03-12	Ali, Asif	Officer	Chief Financial Officer	Direct	Sale	24,903	58.73	$1,462,553.19	62,821	4
2025-02-19	Patel, Dinesh V Ph D	Director,Officer	President and CEO	Direct	Sale	5,359	38.18	$204,606.62	540,260	4
2025-01-16	Molina, Arturo Md	Officer	Chief Medical Officer	Direct	Sale	3,640	0.00	$0.00	83,892	4
2025-01-16	Ali, Asif	Officer	Chief Financial Officer	Direct	Sale	3,918	0.00	$0.00	62,821	4
2024-11-27	Molina, Arturo Md	Officer	Chief Medical Officer	Direct	Sale	26,000	44.66	$1,161,160.00	46,444	4
2024-11-26	Gupta, Suneel	Officer	Chief Development Officer	Direct	Sale	19,191	45.50	$873,190.50	266,983	4
2024-11-26	Patel, Dinesh V Ph D	Director,Officer	President and CEO	Direct	Sale	21,480	46.25	$993,450.00	408,455	4
2024-11-15	Molina, Arturo Md	Officer	Chief Medical Officer	Direct	Sale	1,906	40.98	$78,107.88	46,444	4
2024-09-11	Ali, Asif	Officer	Chief Financial Officer	Direct	Sale	14,203	44.53	$632,459.59	34,960	4
2024-09-10	Waddill, William D.	Director	-	Direct	Sale	8,000	45.00	$360,000.00	12,000	4
2024-07-24	Waddill, William D.	Director	-	Direct	Sale	8,000	40.00	$320,000.00	12,000	4
2024-06-07	Waddill, William D.	Director	-	Direct	Sale	8,000	35.00	$280,000.00	12,000	4
2024-06-07	Patel, Dinesh V Ph D	Director,Officer	President and CEO	Direct	Sale	35,000	35.19	$1,231,650.00	515,415	4
2024-04-18	Ali, Asif	Officer	Chief Financial Officer	Direct	Sale	1,234	25.11	$30,985.74	37,163	4
2024-04-01	Patel, Dinesh V Ph D	Director,Officer	President and CEO	Direct	Sale	25,000	28.31	$707,750.00	549,590	4
2024-03-01	Waddill, William D.	Director	-	Direct	Sale	12,975	31.34	$406,636.50	12,000	4
2024-03-01	Ali, Asif	Officer	Chief Financial Officer	Direct	Sale	14,248	32.28	$459,925.44	38,397	4
2024-03-01	Patel, Dinesh V Ph D	Director,Officer	President and CEO	Direct	Sale	30,000	31.62	$948,600.00	574,590	4
2024-01-09	Gupta, Suneel	Officer	Chief Development Officer	Direct	Sale	5,000	25.00	$125,000.00	187,567	4
2023-12-13	Patel, Dinesh V Ph D	Director,Officer	President and CEO	Direct	Sale	75,000	20.08	$1,506,000.00	534,347	4
2023-11-15	Molina, Arturo Md	Officer	Chief Medical Officer	Direct	Sale	1,848	16.24	$30,011.52	22,527	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

106.47%

Inst. Shares: 69,298,844

Shares Outstanding: 65,087,847

2025-12-31

107.58%

Inst. Shares: 68,391,410

Shares Outstanding: 63,573,048

2025-09-30

107.44%

Inst. Shares: 68,515,061

Shares Outstanding: 63,772,332

2025-06-30

108.70%

Inst. Shares: 69,037,889

Shares Outstanding: 63,510,537

2025-03-31

99.38%

Inst. Shares: 62,572,145

Shares Outstanding: 62,963,806

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	69,298,844	65,087,847	106.47%
2025-12-31	68,391,410	63,573,048	107.58%
2025-09-30	68,515,061	63,772,332	107.44%
2025-06-30	69,037,889	63,510,537	108.70%
2025-03-31	62,572,145	62,963,806	99.38%
2024-12-31	61,220,080	61,566,989	99.44%
2024-09-30	59,269,456	61,767,934	95.96%
2024-06-30	57,421,577	61,305,289	93.66%
2024-03-31	58,471,968	60,855,689	96.08%
2023-12-31	55,911,671	56,763,559	98.50%
2023-09-30	55,023,367	59,182,899	92.97%
2023-06-30	54,273,675	56,775,742	95.59%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Protagonist Therapeutics, Inc (PTGX) — SEC Financial Statements & Analysis

Protagonist Therapeutics, Inc (PTGX) is a pharmaceutical preparations company, incorporated in DE. Protagonist Therapeutics, Inc trades on Nasdaq as: PTGX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Protagonist Therapeutics, Inc reported a -67.24% year-over-year revenue growth, a Debt-to-Equity ratio of 0.05x, a Price-to-Sales (P/S) ratio of 117.96x (TTM), a Price-to-Book (P/B) ratio of 9.60x (TTM), at a market cap of $8.08B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -67.24%
Debt To Equity: 0.05x
P/S TTM: 117.96x
P/B TTM: 9.60x
Market Cap: $8.08B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Protagonist Therapeutics, Inc in?

Protagonist Therapeutics, Inc (PTGX) operates in the Pharmaceutical Preparations industry.

What is PTGX's market cap?

Protagonist Therapeutics, Inc (PTGX) has a market capitalization of $8.08B as of 2026-06-30.

What is PTGX's P/E ratio?

Protagonist Therapeutics, Inc (PTGX)'s trailing twelve month P/E ratio is 97.49x as of 2026-06-30.

What exchange does PTGX trade on?

Protagonist Therapeutics, Inc (PTGX) trades on the Nasdaq.

Where is Protagonist Therapeutics, Inc incorporated?

Protagonist Therapeutics, Inc is incorporated in DE.